Genmab vs Mettler-Toledo International

Genmab (GMAB), health care, and Mettler-Toledo International (MTD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Mettler-Toledo International is worth $34.1B on the stock market and Genmab $32B: Mettler-Toledo International is valued at 6% more. Genmab trades at 44.4 times earnings and Mettler-Toledo International at 37.2. Over the past year Genmab's share price has moved +70.1% and Mettler-Toledo International's +23.7%.

Key facts

Genmab market value
$32B
Mettler-Toledo International market value
$34.1B
Genmab P/E
44.4
Mettler-Toledo International P/E
37.2
Genmab revenue
$3.7BFY to 2025-12-31
Mettler-Toledo International revenue
$4BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Genmab vs Mettler-Toledo International: every measure side by side
Measure Genmab Mettler-Toledo International
SectorHealth CareHealth Care
Country Denmark United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$32Blower$34.1Bhigher
Revenue$3.7Blower$4Bhigher
Earnings$963Mhigher$869.2Mlower
Employees3,244lower16,600higher
Total assets$12.9Bhigher$3.7Blower
Valuation
P/E44.4higher37.2lower
P/S8.6higher8.5lower
P/B—439
Dividend yield—0.00%
Profitability
Operating margin28.6%—
Balance sheet
Net assets$5.8Bhigher-$23.6Mlower
Total liabilities$7Bhigher$3.7Blower
Total debt$5.3Bhigher$2.2Blower
Cash on hand$1.7Bhigher$66.9Mlower
Price change
Today+0.76%higher-0.83%lower
1 year+70.1%higher+23.7%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Genmab only (1)

Mettler-Toledo International only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns GMAB · Who owns MTD

Further comparisons

Learn

Questions and answers

Which is bigger, Genmab or Mettler-Toledo International?

By market value, Mettler-Toledo International is the larger: $34.1B against $32B for Genmab. By revenue in its latest fiscal year, Mettler-Toledo International is the larger: $4B against $3.7B for Genmab.

Which has the higher P/E ratio?

Genmab: 44.4, against 37.2 for Mettler-Toledo International. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has more debt?

Genmab: $5.3B, against $2.2B for Mettler-Toledo International. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Genmab and Mettler-Toledo International?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Genmab and 3 hold Mettler-Toledo International.

Cite this page

Funkfolio, “Genmab vs Mettler-Toledo International”, data as of 17 November 2026. https://funkfolio.com/compare/gmab-vs-mtd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.